In the article the review is presented and pharmacotechnologies for increase of efficiency and safety of medical products are shown, including at the expense of change of bioavailability of molecules of active substances in foci of pathological process and their accelerated metabolism. Analogies have been made between system and topical drug improvements and the principles of comparability in the registration of generic drugs. Demonstrated the possibilities of improving topical drugs. Modern pharmacological science has several obvious trends: there is growing interest in the production of targeted and biological drugs, and new drugs in other (classic) pharmacological groups, which include most of the topical dermatological drugs, are appearing less frequently. There is also a marked focus on improving the way active substances are delivered to their destination. New revolutionary molecules for local therapy are rarely available, and new synthesized substances from previously used anatomical, therapeutic and chemical groups often do not have obvious advantages over drugs already in use for a long time. As a result, output is often not economically feasible. It can be stated that the development of pharmacodynamics (development of new mechanisms of action and new active substances) in local treatment is inferior to the development of pharmacokinetics (a set of processes leading to the creation of a sufficient concentration of the drug in the body, tissue, organ, and cell to form a complex with a biosubstrate). Pharmacology now has a whole discipline, pharmaceutical powder technology, which develops and improves the micro-nanonization and bioavailability of drugs, including dermatological ones. Pharmaceutical powder technology is also associated with particle surface engineering (modeling), usually through chemical and particle surface studies.